NSE · ANUHPHR
Anuh Pharma Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹776 Cr with net profit ₹41 Cr — a 5.29% net margin, versus 7.06% the period before.
Shareholding
As of 2026-06-30
- Promoter71.8%
- Public28.19%
- FII0.01%
- DII0%
27,484 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.49× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Drug Manufacturers - Specialty & Generic · ranked #8 of 15 by market cap · medians across 14 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Alivus Life Sciences Ltd. | ₹17,394 Cr | 27.98 | 5.22 | 16.94% | 23.28% |
| Astrazeneca Pharma India Ltd. | ₹16,783 Cr | 96.74 | 19.23 | 21.49% | 6.97% |
| Akums Drugs & Pharmaceuticals Ltd. | ₹12,167 Cr | 39.85 | 3.67 | 7.7% | 6.48% |
| Procter & Gamble Health Limited | ₹9,064 Cr | 27.2 | 17.28 | 62.32% | 24.91% |
| Gujarat Themis Biosyn Ltd. | ₹5,625 Cr | 120.38 | 7.43 | — | 25.04% |
| Jagsonpal Pharmaceuticals Ltd. | ₹1,504 Cr | 31.98 | 5.48 | 15.6% | 15.47% |
| Bajaj HealthCare Limited | ₹1,101 Cr | 19.56 | 2.07 | 8.81% | 2.81% |
| Anuh Pharma Limited(this company) | ₹931 Cr | 21.06 | 2.64 | 11.65% | 5.67% |
| Bafna Pharmaceuticals Ltd. | ₹750 Cr | 96.41 | 7.8 | 11.54% | 5.46% |
| Amanta Healthcare Limited | ₹734 Cr | 47.85 | 3.33 | 7.46% | 5.04% |
AI analysis
AI-generated · google/gemini-2.5-flashAnuh Pharma Limited, with a market capitalization of Rs 808 Cr, reported revenue of Rs 670.97 Cr and a profit margin of 5.32%. The company's EPS stands at Rs 4.1, and it has a book value of Rs 35.14.
Positives
- +The company has a low debt-to-equity ratio of 0.02.
- +Promoter holding is high at 71.79% as of March 2026.
- +There are no pledged promoter shares (0%).
- +Return on capital employed (ROCE) is 15.53%.
Negatives
- −Revenue growth information is not available in the provided data.
- −The profit margin is 5.32%, which can be considered moderate.
- −The trailing twelve months EPS of Rs 4.1 is lower than the annual EPS of Rs 9.45 reported for March 2025.
Financial Performance
Anuh Pharma Limited reported annual revenue of Rs 670.97 Cr in March 2025. Net profit for the same period was Rs 47.35 Cr, with an EPS of Rs 9.45. Quarterly revenue in March 2026 was Rs 202.12 Cr, with a net profit of Rs 11.68 Cr.
Profitability & Returns
The company's profit margin stood at 5.32%. Return on equity (ROE) was 11.65%, while return on capital employed (ROCE) was 15.53%. The EPS for the latest period is Rs 4.1.
Balance Sheet
Anuh Pharma Limited has a low debt-to-equity ratio of 0.02, indicating minimal reliance on debt financing. The book value per share is Rs 35.14. No information on total assets or liabilities is available in the provided data.
Ownership & Pledges
Public shareholding accounts for 28.16% of the company. There are no promoter shares pledged (0%).
Data as of — price: 2026-09-18 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.